CUREVAC NV (5CV.DE) Stock Fundamental Analysis
FRA:5CV - Deutsche Boerse Ag - NL0015436031 - Common Stock - Currency: EUR
We assign a fundamental rating of 6 out of 10 to 5CV. 5CV was compared to 71 industry peers in the Biotechnology industry. While 5CV has a great health rating, its profitability is only average at the moment. 5CV has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
5CV had positive earnings in the past year.
5CV had a positive operating cash flow in the past year.
In the past 5 years 5CV reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: 5CV reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of 5CV (24.34%) is better than 94.52% of its industry peers.
With an excellent Return On Equity value of 27.94%, 5CV belongs to the best of the industry, outperforming 93.15% of the companies in the same industry.
With an excellent Return On Invested Capital value of 24.75%, 5CV belongs to the best of the industry, outperforming 98.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROIC | 24.75% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
5CV has a better Profit Margin (34.50%) than 93.15% of its industry peers.
With an excellent Operating Margin value of 37.87%, 5CV belongs to the best of the industry, outperforming 93.15% of the companies in the same industry.
With an excellent Gross Margin value of 87.59%, 5CV belongs to the best of the industry, outperforming 84.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 5CV is creating value.
5CV has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for 5CV has been increased compared to 5 years ago.
5CV has a better debt/assets ratio than last year.
2.2 Solvency
5CV has an Altman-Z score of 9.11. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
5CV has a better Altman-Z score (9.11) than 91.78% of its industry peers.
5CV has a debt to FCF ratio of 0.26. This is a very positive value and a sign of high solvency as it would only need 0.26 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.26, 5CV belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that 5CV is not too dependend on debt financing.
5CV has a Debt to Equity ratio of 0.05. This is in the better half of the industry: 5CV outperforms 72.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Altman-Z | 9.11 |
ROIC/WACC3.51
WACC7.06%
2.3 Liquidity
5CV has a Current Ratio of 7.65. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
5CV's Current ratio of 7.65 is amongst the best of the industry. 5CV outperforms 93.15% of its industry peers.
A Quick Ratio of 7.64 indicates that 5CV has no problem at all paying its short term obligations.
5CV's Quick ratio of 7.64 is amongst the best of the industry. 5CV outperforms 93.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 166.39% over the past year.
The Revenue has grown by 787.58% in the past year. This is a very strong growth!
The Revenue has been growing by 98.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
3.2 Future
Based on estimates for the next years, 5CV will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
5CV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.14% yearly.
EPS Next Y-172.19%
EPS Next 2Y-61.36%
EPS Next 3Y-32.41%
EPS Next 5Y-22.5%
Revenue Next Year-84.72%
Revenue Next 2Y-54.11%
Revenue Next 3Y-32.09%
Revenue Next 5Y-11.14%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 4.98, which indicates a rather cheap valuation of 5CV.
5CV's Price/Earnings ratio is rather cheap when compared to the industry. 5CV is cheaper than 95.89% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.25. 5CV is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.98 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 5CV is valued cheaper than 97.26% of the companies in the same industry.
5CV's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 5CV is cheaper than 97.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.34 | ||
| EV/EBITDA | 2.3 |
4.3 Compensation for Growth
5CV has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as 5CV's earnings are expected to decrease with -32.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.36%
EPS Next 3Y-32.41%
5. Dividend
5.1 Amount
No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:5CV (5/30/2025, 7:00:00 PM)
4.032
-0.13 (-3.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners18.11%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap907.85M
Analysts78.46
Price Target5.69 (41.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.37%
Min EPS beat(2)-18.68%
Max EPS beat(2)35.41%
EPS beat(4)2
Avg EPS beat(4)39.95%
Min EPS beat(4)-18.68%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)0.33%
EPS beat(12)5
Avg EPS beat(12)-6.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)15.68%
Min Revenue beat(2)-86.88%
Max Revenue beat(2)118.24%
Revenue beat(4)3
Avg Revenue beat(4)139.54%
Min Revenue beat(4)-86.88%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)58.85%
Revenue beat(12)5
Avg Revenue beat(12)30.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.59%
PT rev (3m)-24.65%
EPS NQ rev (1m)137.5%
EPS NQ rev (3m)137.5%
EPS NY rev (1m)0.64%
EPS NY rev (3m)-2.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)20.56%
Revenue NY rev (3m)6.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.98 | ||
| Fwd PE | N/A | ||
| P/S | 1.73 | ||
| P/FCF | 6.34 | ||
| P/OCF | 5.78 | ||
| P/B | 1.4 | ||
| P/tB | 1.46 | ||
| EV/EBITDA | 2.3 |
EPS(TTM)0.81
EY20.09%
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)0.64
FCFY15.77%
OCF(TTM)0.7
OCFY17.3%
SpS2.33
BVpS2.87
TBVpS2.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROCE | 29.12% | ||
| ROIC | 24.75% | ||
| ROICexc | 70.54% | ||
| ROICexgc | 78.69% | ||
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% | ||
| FCFM | 27.34% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Debt/EBITDA | 0.15 | ||
| Cap/Depr | 74.88% | ||
| Cap/Sales | 2.65% | ||
| Interest Coverage | 85.86 | ||
| Cash Conversion | 72.42% | ||
| Profit Quality | 79.25% | ||
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 | ||
| Altman-Z | 9.11 |
F-Score8
WACC7.06%
ROIC/WACC3.51
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y-172.19%
EPS Next 2Y-61.36%
EPS Next 3Y-32.41%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
Revenue Next Year-84.72%
Revenue Next 2Y-54.11%
Revenue Next 3Y-32.09%
Revenue Next 5Y-11.14%
EBIT growth 1Y168.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-145%
EBIT Next 3Y-28.88%
EBIT Next 5Y10.78%
FCF growth 1Y142.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y162.99%
OCF growth 3YN/A
OCF growth 5YN/A